Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Start line on the highway
Stocks for Beginners

You Don’t Need a Ton of Money to Grow a Successful TFSA: Here Are 3 Ways to Get Started

These TSX stocks have a higher likelihood of delivering returns that outpace the broader market, making them top bets for…

Read more »

todder holds a gold bar
Metals and Mining Stocks

With Copper and Gold Surging, the Canadian Mining Stocks You Need to Know About

As the commodity rally in metals continues, some Canadian mining stocks are emerging as winners over others. Here are two…

Read more »

Female raising hands enjoying vacation, standing on background of blue cloudless sky.
Dividend Stocks

It’s a Wonderful Lifetime Strategy: Buy and Hold Dividend Stocks Forever

CN Rail (TSX:CNR) stock looks like a dividend bargain worth holding forever in a TFSA or RRSP.

Read more »

a woman sleeps with her eyes covered with a mask
Dividend Stocks

The “Sleep-Well” TFSA Portfolio for 2026: 3 Blue-Chip Stocks to Buy in January

A simple “sleep-better” TFSA core for January 2026 can start with a bank, a utility, and an energy blue chip,…

Read more »

stocks climbing green bull market
Investing

Invest in These Unstoppable Canadian Stocks for the Next 5 Years

Looking for unstoppable Canadian stocks to hold for the next five years (or more)? Aritzia and TerraVest might be just…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Stocks Retirees Should Absolutely Love

Discover strategies for managing stocks during retirement, especially in light of market uncertainties and downturns.

Read more »

Person holds banknotes of Canadian dollars
Dividend Stocks

This Monthly Dividend Stock Could Make January Feel Like Payday Season

Freehold Royalties’ 8% yield can make your TFSA feel like “payday season,” but that monthly cheque is tied to energy…

Read more »

Canada Day fireworks over two Adirondack chairs on the wooden dock in Ontario, Canada
Tech Stocks

Down 38%, This Magnificent Canadian Stock Could Be the Biggest Bargain on the TSX Today

Constellation Software (TSX:CSU) was a tough hold in 2025, could the new year be a turning point.

Read more »